February 2015 MY CHILD MATTERS: THE FIGHT AGAINST CHILDHOOD CANCER: PHILIPPINES CASE STUDY PRESS KIT
p.2 Key figures CONTENTS p.3 My Child Matters in the Philippines: promoting comprehensive management of the disease p.5 The fight against childhood cancer: 10 years of commitment by the Sanofi Espoir Foundation and the My Child Matters program p.7 Philippines overview p.9 The organization of the healthcare system in the Philippines p.10 Sanofi in the Philippines p.11 Sanofi Espoir Foundation p.12 Sanofi Group G. Corre Tristan Parry
Key figures Worldwide 175, 000 children confronted with cancer every year around the world (source : SIOP November 2013) 90, 000 deaths annually In industrialized and low-resource countries, the five-year survival rate can fall from 80% to 20% or even as low as 10% (source: UICC) In the Philippines About 3,500 Filipino children will develop cancer each year; only about 1/3 will be diagnosed and treated in medical facilities Leukemia, lymphoma, and retinoblastoma accounts for about 60-70% of all childhood cancers seen in hospitals Although multimodal management is available and could potentially cure 80% of patients, less than 20% will survive long-term 2/3 of cases are presented in advanced stages when a cure is no longer possible, or can only be achieved using very aggressive and expensive treatment available only in large centers, which patients cannot afford Families will often opt not to undergo treatment due to financial constraints A significant number of patients are unable to continue follow-up visits leading to rates of abandonment of care as high as 80% Philippine Children s Medical Center 2
My Child Matters in the Philippines: promoting comprehensive management of the disease Given the geography of the Philippines, an archipelago of thousands of islands, movement is not easy and rural areas are isolated. The main problem for good management of cancer in the Philippines is that two-thirds of the children arrive at the Manila hospital too late, says Dr. Julius Lecciones, executive director of the Philippine Children s Medical Center. A diagnosis at a stage that is too late, the cost of expensive treatment, abandonment of treatment and false beliefs are obstacles that explain the low survival rate we observed at the outset. The My Child Matters program enables: - organization of an information campaign to deliver key messages and improve information for families; - facilitating patient access to diagnosis and care; - ensuring treatment coverage by health insurance. After nearly 10 years, the results of these actions can be seen through a rate of early diagnosis in 70% of cases today. Abandonment of treatment divided by 8 Since 2006, the program has enabled a network of 31 facilities to be established to support children outside the capital. From 20 pediatric oncologist-hematologists at the start, the workforce now includes 56 doctors. The medications, primarily from donations, are now better supported by the national health insurance system, which created the «Philhealth Z package, starting with treatments for leukemia, the most widespread of childhood cancers. The treatment abandonment rate has been decreased from 80% to 10%. The Philippines Children s Medical Center in Manila has become a national reference center with a survival rate that has been improved from 16% in 2010 to 78% in 2012. Philippine Children s Medical Center 3
Maintaining Positive momentum with government commitment The government is currently considering a comprehensive program to fight cancer. The government is now listening, says Dr. Julius Lecciones, This would not have happened if we had not initiated an information campaign to raise awareness. The issue was brought to the attention of Congress, which allocates budgets. We need to maintain the momentum or all progress will be lost. My Child Matters has accelerated the development of pediatric oncology as a professional discipline in the Philippines. A degree is awarded after three years of residency and two years of specialization. The program has also demonstrated the value of international cooperation with key organizations and agencies. results Late diagnosis reduced from 70% to 30% Treatment abandonment rate decreased from 80% to just 10% Overall survival rate improved from 16% in 2010 to 78% in 2012 (source: Hospital data from Philippines Children s Medical Center/other hospitals in the My Child Matters Philippines/DOH-NCPAM network) 3 Philippine Children s Medical Center 4
The fight against childhood cancer: 10 years of commitment by the Sanofi Espoir Foundation My Child Matters: a program to improve the survival of children with cancer in countries with limited resources Five-year survival for a child with cancer in developed countries is 80%, while it is only 20% on average in countries with limited resources, or even 10% for the least developed countries. The significant improvement in survival from pediatric cancers in developed countries shows that many of these cancers are curable, says Dr. Raul Ribeiro, pediatric oncologist at St. Jude Research Hospital in the US and chairman of the expert committee. No child should die of cancer when treatments that can cure exist. It is imperative that the authorities recognize this and take measures to ensure that children are correctly diagnosed and receive appropriate treatment. After An initiative of the Sanofi Espoir Foundation The My Child Matters program, developed by the Sanofi Espoir Foundation and deployed with experts from the St. Jude Children s Research Hospital and associations such as the SIOP, UICC, GFAOP and CCI, combines financial support, support from international experts and networking to improve all aspects of the healthcare system. The primary goals of My Child Matters: providing information and increasing awareness by the public and authorities, training qualified personnel, early diagnosis, access to care - including the fight against pain and provision of palliative care, an area that is still very underdeveloped - and psychological support for children, families and caregivers. Since 2006, five calls for proposals were launched jointly by the Sanofi Espoir Foundation with 33 countries. Institutions, hospitals and NGOs can submit project proposals that are reviewed by a committee - chaired by Dr. Raul Ribeiro, Director of the leukemia and lymphoma division at St. Jude Children s Research Hospita, US - and bringing together world experts in childhood cancer and infant health. This committee selects the projects, decides the allocation of financial support and identifies a «mentor to support the project leader and the team. 10 years of action: sustainable progress achieved More than 45 projects have been supported in 33 countries. Today, 13 projects are underway on three continents: Asia, Africa and Latin America. The local success of these projects has led certain governments to recognize that childhood cancer is a healthcare priority and thereafter promote its treatment as part of their national health program. By virtue of these kinds of decisions, we can sustainably improve care for children s cancers, says My Child Matters Program Director, Dr. Anne Gagnepain-Lacheteau. 5
My Child Matters: an initiative of the Sanofi Espoir Foundation 2006: creation of the partnership and the first call for project proposals Since 2006: 45 projects have been supported in 33 countries Currently: 13 projects (including 9 multi-country) Africa: Burkina Faso, Cameroon, Ivory Coast, Madagascar, Mali, Morocco, Democratic Republic of Congo, Senegal; Asia: Pakistan, Philippines, Thailand; Latin America: Colombia, Guatemala, Honduras, Paraguay Areas: documenting of cancers within the population, early diagnosis, decentralization to provide patients with treatment and palliative care closer to home. 8 out of 13 of these projects involve inter-regional health networks A number of awareness campaigns have been deployed with the UICC, helping to make children s cancer a public health priority. Main partners: St. Jude Research Hospital, US International Society of Paediatric Oncology (SIOP) Union for International Cancer Control (UICC) French-African pediatric oncology group (GFAOP) Children Cancer Institute (CCI) Asia: Among the actions of «My Child Matters Thailand: implementation of the project «From cure to care, to make life easier for families of a child with cancer. Africa: establishment of a network of screening and treatment of retinoblastoma in Mali, with deployment in Democratic Republic of Congo, Ivory Coast, Senegal and Madagascar Latin America: Colombia: establishment of the first childhood cancer monitoring system (called Vigicancer) in the Cali region, enabling the collection of epidemiological data and improved monitoring of children to decrease treatments abandonments. Paraguay: Childhood Cancer Care Network (Red Nacional para la Atencion al Cancer Infantil or ReNACI): create a network of satellite clinics spread across the main regions from where patients were referred to the cancer center. 6
Philippines Country Profile Summary Overview Population: 100 million, with a median age of 23.5 years and urbanization at 48.8% Filipinos are 95% Christian (83% are Catholic) and 5% Muslim (residing mostly in the south) Health Disease: - Heart disease and diabetes are among the top 10 leading causes of death - Around 5 million Filipinos have diabetes with many of them undiagnosed/untreated - Top 10 causes of Mortality (latest available data): MORTALITY: TEN (10) LEADING CAUSES NUMBER AND RATE/100,000 POPULATION Philippines 5-Year Average (2004-2008) & 2009 CAUSES 5-Year Average 2009* (2004-2008) Number Rate Number Rate 1. Diseases of the Heart 82,290 94.5 100,908 109.4 2. Diseases of the Vascular System 55,999 64.3 65,489 71.0 3. Malignant Neoplasms 43,185 49.6 47,732 51.8 4. Pneumonia 35,756 41.1 42,642 46.2 5. Accidents** 34,704 39.9 35,990 39.0 6. Tuberculosis, all forms 25,376 29.2 25,470 27.6 7. Chronic lower respiratory diseases 20,830 24.0 22,755 24.7 8. Diabetes Mellitus 19,805 22.7 22,345 24.2 9.Nephritis, nephrotic syndrome and nephrosis 11,612 13.4 13,799 15.0 10. Certain conditions originating in the perinatal period 12,590 14.5 11,514 12.5 7
Government Archipelago of over 7,100 islands with a political territory of 300,000 square kilometers A democratic republic with a unitary, presidential form of government and a bicameral legislature similar to the United States Unlike the United States, however, the President and the Vice President are separately elected and can come from different political parties as has been the case for the last few elections Stable political environment led by current President Benigno S. Aquino III who serves until 2016 and cannot be re-elected Economy Per capita income (PPP): US$4,682, GDP at US$250B, growing at average 6% in the last 3 years Projections for LRP period* Real GDP growth (%) (source: Asian Development Bank, Citibank and UBS) 2013 2014 2015 2016 2017 6.6% 6.1% 6-7% 6-7% 6-7% CPI inflation (%) 3.8% 4% 4% 4% 4% Unemployment (%) 7.5% 7% 7% 7% 7% 8
The organization of the healthcare system in the Philippines Healthcare System* Total healthcare spending was at USD$ 9.3 Billion in 2010 - Public healthcare investment grew from USD$ 0.8 Billion in 2011 to about USD$ 1.4 Billion in 2013 Healthcare spending represents around 4.1% of GDP 1 MD per 10,000 Filipinos; 1 hospital bed per 1,000 Filipinos Split between private (70%) and public (30%) has not changed significantly in the past several years Universal health care program by government is currently limited to public health insurance coverage for the poorest 27% of the population Pharmaceutical Industry* Total market in 2013 at USD$ 3.0 Billion with 5.8% growth. -Ethical which is 70% of the market grew by 6.5% driven by Branded Generics (7.1%) -OTC grew by 4.4%. (*source: Official government & industry data of the Philippines) 9
Sanofi in the Philippines - Sanofi has 3 legal entities in Philippines, with 584 employees Sanofi Aventis established 1965 with more than 400 employees; - Sanofi Pasteur established 1978, almost 100 employees; - Merial established 1978 Key products: -Pharma: Top 5 ~ 51% of total (Lactacyd, Lantus, Essentiale, Aprovel & Plavix) -Vaccines: Top 3 ~ 51% (Vaxigrip, Verorab & Pneumo) Ranked No. 7 with a 3.4% market share pine Corporate Social Responsibility (CSR) focused My Child Matters on pediatric cancer and humanitarian assistance during natural disasters; CSR partners include the Philip- Children s Medical Center and the Philippine Red Cross. 10
Sanofi Espoir Foundation The Sanofi Espoir Corporate Foundation was created in October 2010 by Sanofi to leverage more than 20 years of commitment to international solidarity. It is dedicated to helping reduce healthcare inequalities, particularly among the world s most needy communities, as part of its social responsibility agenda. Its actions revolve around three major objectives: fighting against childhood cancer, fighting against maternal and neonatal mortality, and ensuring access to healthcare for the world s poorest populations in France and abroad through pilot programs of health insurance. In 2014, the Foundation partnered 42 long term programs for its 3 priorities, with 35 main partners in 30 beneficiary countries For more information: http://fondation-sanofi-espoir.com/en/ 11
Sanofi Sanofi is a global healthcare company focused on patient needs and engaged in the research, development, manufacturing and marketing of healthcare products. The Sanofi Group is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur and Animal Health via Merial Limited (Merial) of which we are world leaders. As a global diversified healthcare company our business includes a diversified offering of medicines, consumer healthcare products, generics, animal health and human vaccines. As a leading healthcare company, Sanofi s mission is to protect the health, improve the quality of life and meet the hopes and potential needs of 7 billion people in the world. We are present in approximately 100 countries on five continents with 112,128 employees at year end 2013. In 2014, net sales amounted to 33,770 million euros. 12
For more information http://csr.sanofi.com Contact Laurence Bollack Media relations Tel. + (33) 01 53 77 46 46 mr@sanofi.com